Literature DB >> 15334475

The V(lambda)-J(lambda) repertoire of patients with systemic lupus erythematosus manifests characteristics of the natural antibody repertoire.

Jisoo Lee1, Young Joo Cho, Peter E Lipsky.   

Abstract

OBJECTIVE: To understand in detail the mechanisms of autoantibody production in patients with systemic lupus erythematosus (SLE), we performed a comprehensive analysis of the normal human immunoglobulin light chain V(lambda) repertoire and compared it with the V(lambda) repertoire in SLE patients.
METHODS: The SLE V(lambda) repertoire of B cells obtained from 3 SLE patients was analyzed and compared in detail with the V(lambda) repertoire of IgM+ B cells obtained from 3 human fetal spleens and IgM+,CD5+ B cells obtained from 2 normal adults. Conventional IgM+,CD5- B cells obtained from normal adults were used as controls. V(lambda)-J(lambda) rearrangements were amplified from the genomic DNA of individual B cells by polymerase chain reaction.
RESULTS: The expressed V(lambda) repertoire of SLE patients contained several similarities with the expressed repertoire of the fetus and the adult CD5+ B cells. The V(lambda) genes 3L and 1G were overexpressed in the fetus, the adult CD5+ B cells, and the patients with SLE. The selection for rearrangements with restricted junctional diversity by utilization of homology-mediated joining, together with diminished N nucleotide addition, was a prominent feature of fetal, adult CD5+, and SLE B cell repertoires. Furthermore, profound expansion of V(lambda) clones with identical third complementarity-determining regions was observed in the adult CD5+, fetal, and SLE B cell repertoires. Notably, significant numbers of expanded adult CD5+ B cells, fetal, and SLE V(lambda) clones utilized homology-mediated joining at the V(lambda)-J(lambda) junctions.
CONCLUSION: These data demonstrate that the SLE V(lambda)-J(lambda) repertoire manifests characteristics of normal adult IgM+,CD5+ and fetal B cell populations that are known to be enriched for the production of natural autoantibodies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15334475     DOI: 10.1002/art.20439

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  7 in total

1.  In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis.

Authors:  Anthony Chang; Scott G Henderson; Daniel Brandt; Ni Liu; Riteesha Guttikonda; Christine Hsieh; Natasha Kaverina; Tammy O Utset; Shane M Meehan; Richard J Quigg; Eric Meffre; Marcus R Clark
Journal:  J Immunol       Date:  2010-12-27       Impact factor: 5.422

Review 2.  Do antiphospholipid antibodies develop for a purpose?

Authors:  Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

Review 3.  B cells in autoimmune diseases: insights from analyses of immunoglobulin variable (Ig V) gene usage.

Authors:  Angela Lee Foreman; Judy Van de Water; Marie-Lise Gougeon; M Eric Gershwin
Journal:  Autoimmun Rev       Date:  2007-01-12       Impact factor: 9.754

4.  Immunoglobulin light-chain genes in the rhesus macaque II: lambda light-chain germline sequences for subgroups IGLV1, IGLV2, IGLV3, IGLV4 and IGLV5.

Authors:  Wendy A Howard; Jon M Bible; Eva Finlay-Dijsselbloem; Sam Openshaw; Deborah K Dunn-Walters
Journal:  Immunogenetics       Date:  2005-10-18       Impact factor: 2.846

5.  Analysis of RAG expression by peripheral blood CD5+ and CD5- B cells of patients with childhood systemic lupus erythematosus.

Authors:  H Morbach; S K Singh; C Faber; P E Lipsky; H J Girschick
Journal:  Ann Rheum Dis       Date:  2005-08-26       Impact factor: 19.103

6.  B cell receptor light chain repertoires show signs of selection with differences between groups of healthy individuals and SLE patients.

Authors:  Nathan Schoettler; Dongyao Ni; Martin Weigert
Journal:  Mol Immunol       Date:  2012-04-18       Impact factor: 4.407

Review 7.  The Role of B1 Cells in Systemic Lupus Erythematosus.

Authors:  Zhou She; Cuifang Li; Feifeng Wu; Jueyi Mao; Min Xie; Marady Hun; Amin Sheikh Abdirahman; Senlin Luo; Wuqing Wan; Jidong Tian; Chuan Wen
Journal:  Front Immunol       Date:  2022-03-28       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.